---
date: 2023-08-29
image: https://i.postimg.cc/QC7zs2fy/09-01.jpg
tags:
- GCP
- Regulations
- Position Informations
title: Roles & Responsibilities
---

许多个人和团体参与临床研究。根据良好临床实践 (GCP) 指南的定义，申办者和首席研究员的核心角色是。

对于其他个人和团体定义了额外的角色和责任，他们的工作对于临床研究的正确进行至关重要。这些角色的引用方式可能因研究网络而异。

该模块将：

> 讨论GCP指南中概述的申办者和首席研究员的角色和责任。
>
> 简要描述这些角色和职责在临床研究中是如何履行的。
>
> 讨论参与研究的其他个人和团体的角色和责任。

**按角色划分的职责**

以下是GCP指南中根据角色概述的职责摘要

<div id="tabID" class="nested-tab-interactive interactive"><div class="vertical-tabs-container"><div class="tab-title"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">核心角色</font></font></div><div class="vertical-tabs-option-container"><ul class="nav nav-tabs vertical-tabs" data-tabs="tabs"><li class="vertical-tab active"><div data-toggle="pill" href="#vertTab-index-0"><img class="img-responsive" src="/assets/img/role_icons/SS_01.png"><div class="vertical-tab-title"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">赞助</font></font></div><div class="selected-indicator"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">&gt;</font></font></div></div></li><li class="vertical-tab"><div data-toggle="pill" href="#vertTab-index-1"><img class="img-responsive" src="/assets/img/role_icons/PI_01.png"><div class="vertical-tab-title"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">首席研究员</font></font></div><div class="selected-indicator"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">&gt;</font></font></div></div></li><li class="vertical-tab"><div data-toggle="pill" href="#vertTab-index-2"><img class="img-responsive" src="/assets/img/role_icons/LI_01.png"><div class="vertical-tab-title"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">其他角色</font></font></div><div class="selected-indicator"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">&gt;</font></font></div></div></li><li class="vertical-tab"><div data-toggle="pill" href="#vertTab-index-3"><img class="img-responsive" src="/assets/img/role_icons/RC_01.png"><div class="vertical-tab-title"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">研究</font></font><br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">现场工作人员</font></font></div><div class="selected-indicator"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">&gt;</font></font></div></div></li></ul></div></div><div class="vertical-tabs-content-container tab-content"><div id="vertTab-index-0" class="tab-pane fade active in"><ul class="nav nav-pills"><li class="active"><a data-toggle="pill" href="#tabID-index-00"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">监控</font></font></a></li><li class=""><a data-toggle="pill" href="#tabID-index-01"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">质量保证和质量控制</font></font></a></li><li class=""><a data-toggle="pill" href="#tabID-index-02"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">专业知识</font></font></a></li><li class=""><a data-toggle="pill" href="#tabID-index-03"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">研究设计与管理</font></font></a></li><li class=""><a data-toggle="pill" href="#tabID-index-04"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">义务转移</font></font></a></li></ul><div class="tab-content"><div id="tabID-index-00" class="tab-pane fade active in"><h2><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">数据和安全监控</font></font></h2><p><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">所有 NIH 支持的多中心 III 期临床试验都必须有独立的数据和安全监测委员会 (DSMB)。</font><font style="vertical-align: inherit;">这一要求适用于药物治疗研究和行为研究。</font></font></p><p><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">每个 DSMB 的成员包括疾病领域、治疗、临床试验设计、生物统计学和研究伦理方面的专家。</font><font style="vertical-align: inherit;">DSMB 由主办方任命并向主办方报告。</font><font style="vertical-align: inherit;">他们的作用是：</font></font></p><ul><li><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">通过熟悉研究、提出适当的分析并审查可用的结果和安全数据来保护参与者的安全。</font></font></li><li><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">通过审查参与者登记、现场访问、研究程序、表格填写、数据质量、随访损失以及遵守研究方案的其他措施等问题的数据，确保研究的完整性。</font></font></li><li><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">监测不良事件，并在必要时建议改变研究方案或操作。</font><font style="vertical-align: inherit;">这种监测功能超出了 IRB 传统上提供的监督范围，对于多中心研究尤为重要。</font></font></li></ul><p><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">单击</font></font><a href="http://grants.nih.gov/grants/guide/notice-files/not98-084.html" target="_blank"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">此处</font></font></a><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">查看 NIH 关于数据和安全监测的政策文件。</font></font></p></div><div id="tabID-index-01" class="tab-pane fade"><h2><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">质量保证和质量控制（ICH GCP 5.1）</font></font></h2><p><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">申办者负责实施和维护质量保证和质量控制系统，以确保研究的进行和记录符合方案、GCP 和监管要求。</font></font></p></div><div id="tabID-index-02" class="tab-pane fade"><h2><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">医学专业知识（ICH GCP 5.3）</font></font></h2><p><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">申办者负责指定具有适当资格的医务人员，就与试验相关的医疗问题或问题提供建议。</font></font></p></div><div id="tabID-index-03" class="tab-pane fade"><h2><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">研究设计和管理（ICH GCP 5.4、5.5）</font></font></h2><p><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">申办者负责指定合格的人员来执行研究过程的所有阶段，包括：</font></font></p><ul><li><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">设计协议。</font></font></li><li><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">监督研究的整体进行。</font></font></li><li><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">管理和验证研究数据。</font></font></li><li><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">确保人类参与者的安全和权利。</font></font></li><li><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">监控学习表现。</font></font></li><li><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">规划并进行统计分析。</font></font></li><li><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">准备研究报告。</font></font></li></ul></div><div id="tabID-index-04" class="tab-pane fade"><h2><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">审判相关义务的转移</font></font></h2><p><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">申办者可以将申办者的任何或所有与试验相关的职责和职能转移给合同研究组织 (CRO)。</font><font style="vertical-align: inherit;">然而，试验数据的质量和完整性的最终责任始终由申办者承担。</font><font style="vertical-align: inherit;">任何转移给 CRO 并由其承担的与试验相关的职责和职能均以书面形式规定。</font><font style="vertical-align: inherit;">申办者应确保对其代表其履行的任何试验相关职责和职能进行监督，包括由申办者签约 CRO 分包给另一方的试验相关职责和职能（参见 ICH GCP E6 5.2.2）。</font></font></p></div></div></div><div id="vertTab-index-1" class="tab-pane fade"><ul class="nav nav-pills"><li class="active"><a data-toggle="pill" href="#tabID-index-10"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">概述</font></font></a></li><li class=""><a data-toggle="pill" href="#tabID-index-11"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">资格和经验</font></font></a></li><li class=""><a data-toggle="pill" href="#tabID-index-12"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">关爱参与者</font></font></a></li><li class=""><a data-toggle="pill" href="#tabID-index-13"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">沟通</font></font></a></li><li class=""><a data-toggle="pill" href="#tabID-index-14"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">遵守</font></font></a></li><li class=""><a data-toggle="pill" href="#tabID-index-15"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">产品的使用</font></font></a></li><li class=""><a data-toggle="pill" href="#tabID-index-16"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">随机化和盲法</font></font></a></li><li class=""><a data-toggle="pill" href="#tabID-index-17"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">知情同意书</font></font></a></li><li class=""><a data-toggle="pill" href="#tabID-index-18"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">记录和报告</font></font></a></li><li class=""><a data-toggle="pill" href="#tabID-index-19"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">暂停和终止</font></font></a></li></ul><div class="tab-content"><div id="tabID-index-10" class="tab-pane fade in active"><h2><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">概述</font></font></h2><p><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">首席研究员 (PI) 通常是主要研究中心的 PI，负责在该中心进行临床研究。</font><font style="vertical-align: inherit;">对于多中心试验，有许多研究中心，每个研究中心都有自己负责监督的首席研究员和参与研究进行的工作人员。</font></font></p><p><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">即使特定任务被委托给其他现场研究人员，PI 仍保留最终的监督责任。</font><font style="vertical-align: inherit;">此外，PI 的职责包括：</font></font></p><ul><li><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">记录向合格且经过充分培训的研究人员的研究职责的授权。</font></font></li><li><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">监督研究表现并监督研究地点研究人员的表现。</font></font></li><li><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">确保：</font></font><ul><li><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">参与者的福祉和安全受到保护。</font></font></li><li><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">所有研究程序均按照方案和 GCP 在研究地点进行。</font></font></li></ul></li><li><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">为参与研究的所有员工制定沟通计划。</font></font></li><li><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">监督研究产品的责任。</font></font></li></ul><p><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">值得注意的是，PI 必须以该身份签署协议签名页。</font><font style="vertical-align: inherit;">如果研究是根据</font></font><a href="/modules/11" target="_blank"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">研究性新药</font></font></a><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">(IND) 申请进行的，PI 还必须签署</font></font><a href="http://www.fda.gov/downloads/aboutfda/reportsmanualsforms/forms/ucm074728.pdf" target="_blank"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">FDA 1572 表。如果研究免于 IND 要求，PI 必须签署研究者协议。</font></font></a></p></div><div id="tabID-index-11" class="tab-pane fade "><h2><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">资格和经验（ICH GCP 4.1 和 4.2）</font></font></h2><p><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">PI 必须：</font></font></p><ul><li><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">通过教育、培训和经验获得资格，承担正确开展研究的责任。</font></font></li><li><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">如果研究涉及使用研究产品，请彻底熟悉研究方案中所述的该产品的正确使用方法。</font></font></li><li>Be aware of and remain in compliance with GCP and applicable regulatory requirements.</li><li>Maintain a list of qualified persons to whom he or she delegates significant study-related duties.</li><li>Maintain supervisory responsibility for any individual or party delegated to trial-related duties and functions conducted at the trial site.</li><li>Implement procedures to ensure the integrity of the trial-related duties and functions performed and any data generated.</li></ul></div><div id="tabID-index-12" class="tab-pane fade "><h2>Medical Care of Study Participants (ICH GCP 4.3)</h2><ul><li>All study participants should receive appropriate medical care both for study-related adverse events and for all medical conditions unrelated to study participation.</li><li>A qualified physician affiliated with the study should be responsible for all study-related medical decisions.</li><li>The participant’s primary care physician should be informed about the participant’s involvement in the study, provided that the participant:<ul><li>Has a primary care physician.</li><li>Agrees that the primary care physician may be informed.</li></ul></li></ul></div><div id="tabID-index-13" class="tab-pane fade "><h2>Communication with Institutional Review Board (ICH GCP 4.4)</h2><p>The PI is identified to the designated IRB.  Before and during a study, the PI must comply with all requirements of the designated Institutional Review Boards (IRBs). A study may not begin prior to obtaining IRB approval. (See material regarding the <a href="/modules/9/3" target="_blank">Investigators’ responsibilities to the IRB</a> from the <a href="/modules/1" target="_blank">Institutional Review Boards module</a>.)</p></div><div id="tabID-index-14" class="tab-pane fade "><h2>Compliance with the Protocol (ICH GCP 4.5)</h2><p>The PI is responsible for ensuring that the study is conducted in compliance with the <a href="/modules/9/3" target="_blank">research protocol</a>. He or she should ensure that all protocol violations are identified, documented, and reported in accordance with CTN and IRB requirements. Repeated protocol violations may indicate that protocol amendments, procedural changes, or additional training are needed.</p></div><div id="tabID-index-15" class="tab-pane fade "><h2>Use of Investigational Products (ICH GCP 4.6)</h2><p>If the study involves the use of an investigational product, the PI is responsible for ensuring that the investigational product is used only in accordance with the study protocol and federal regulations; and that accountability of the investigational product is maintained. (See related material from the <a href="/modules/9" target="_blank">Investigational New Drugs module</a>.)</p><p>For clinical investigations that use controlled study drug, the PI may be required to have a medical license.  When the PI is not required to have a medical license, responsibility for receiving or administering certain drugs, reviewing safety events, and making independent medical decisions is delegated to qualified medical personnel, such as a physician, physician’s assistant, nurse practitioner , or other qualified/licensed medical professional.  These delegated responsibilities are documented in the site’s delegation of responsibilities log, and the staff assigned may serve as a sub-investigator.  Consult local regulations and oversight authorities on medical license requirements for conducting research using controlled drug.</p></div><div id="tabID-index-16" class="tab-pane fade "><h2>Randomization and Blinding (ICH GCP 4.7)</h2><p>The PI is responsible for ensuring that the study’s procedures, if any, for <a href="/modules/9/3" target="_blank">randomization and blinding</a>  are followed.</p></div><div id="tabID-index-17" class="tab-pane fade "><h2>Informed Consent (ICH GCP 4.8)</h2><p>The PI is responsible for ensuring that procedures for obtaining and documenting informed consent comply with GCP and with the ethical principles originating in the Declaration of Helsinki.</p></div><div id="tabID-index-18" class="tab-pane fade "><h2>Records and Reports (ICH GCP 4.9)</h2><p>The PI is responsible for ensuring that  all study data that are reported to the Sponsor are accurate, legible, contemporaneous, original, accurate, and complete. Changes to the source data should be traceable, should not obscure the original entry, and should be explained if necessary (e.g., via an audit trail).</p><p>The PI should provide written reports on the status of the study to the Sponsor and IRB when and as often as required to do so at each institution where the study is conducted.</p><p>All serious adverse events must be reported immediately to the Sponsor. The PI must also comply with regulatory requirements to report serious adverse events to the IRB and regulatory authorities.</p><h2>Final Study Reports (ICH GCP 4.13)</h2><p>On completion of the study, the PI is responsible for providing:</p><p>All required reports to the Sponsor and regulatory authorities.</p><p>A summary of the study outcome to the Institutional Review Board.</p><p>Records and reports are discussed in greater detail in the Documentation and Record Keeping module. Serious adverse events are discussed in the Participant Safety and Adverse Events module.</p></div><div id="tabID-index-19" class="tab-pane fade "><h2>Premature Suspension or Termination of Study (ICH GCP 4.12)</h2><p>If the study is suspended or stopped early for any reason, the PI is responsible for:</p><ul><li>Promptly informing all study participants.</li><li>Ensuring that all participants receive appropriate therapy and follow-up.</li><li>Complying with all requirements to inform regulatory authorities.</li></ul></div></div></div><div id="vertTab-index-2" class="tab-pane fade"><ul class="nav nav-pills"><li class="active"><a data-toggle="pill" href="#tabID-index-20">Overview</a></li><li class=""><a data-toggle="pill" href="#tabID-index-21">QA</a></li><li class=""><a data-toggle="pill" href="#tabID-index-22">Training</a></li><li class=""><a data-toggle="pill" href="#tabID-index-23">Regulatory Affairs</a></li></ul><div class="tab-content"><div id="tabID-index-20" class="tab-pane fade active in"><h2>Overview</h2><p>The investigator convenes a Protocol Team to assist with all aspects of the operation of the study. In addition to the responsibilities listed under Principle Investigator, other responsibilities represented on the Protocol Team usually include, but are not limited to, Quality Assurance, Training, and Regulatory Affairs.</p></div><div id="tabID-index-21" class="tab-pane fade"><h2>Quality Assurance</h2><p>Quality Assurance (QA) staff is responsible for:</p><ul><li>Reviewing the protocol to check for inconsistencies and problematic wording that will increase the likelihood of protocol violations.</li><li>Reviewing monitoring reports of site visits to ensure that all identified issues are addressed in an appropriate and timely fashion and are communicated to the investigative team.</li><li>Conducting site visits on the behalf of the Sponsor as needed.</li></ul></div><div id="tabID-index-22" class="tab-pane fade"><h2>Training</h2><p>Training staff is responsible for:</p><ul><li>Developing a study-specific training plan.</li><li>Ensuring that all training of study staff is conducted as planned and documented on the study specific training log.</li></ul></div><div id="tabID-index-23" class="tab-pane fade"><h2>Regulatory Affairs</h2><p>Regulatory Affairs staff is responsible for:</p><ul><li>Writing the study informed consent documents.</li><li>Submitting the protocol, consent documents, and Institutional Review Board (IRB) documents to the IRB and making any changes in those documents required by the IRB.</li><li>Distributing the IRB-approved protocol, consent documents, and Institutional Review Board (IRB) documents to participating research sites to assist them in preparing their IRB submissions.</li><li>Preparing and distributing a checklist of items that participating sites must have, and</li><li>Providing regulatory guidance to the study sites as necessary.</li></ul><p>This responsibility continues throughout the duration of the trial e.g. submission of a Protocol Amendment.</p></div></div></div><div id="vertTab-index-3" class="tab-pane fade"><ul class="nav nav-pills"><li class="active"><a data-toggle="pill" href="#tabID-index-30">Research Coordinator/Assistant</a></li><li class=""><a data-toggle="pill" href="#tabID-index-31">Other Staff</a></li></ul><div class="tab-content"><div id="tabID-index-30" class="tab-pane fade active in"><h2>Research Coordinator/Assistant</h2><p>Under the supervision of the PI at the site, examples of responsibilities for the Research Coordinator/Assistant may include:</p><ul><li>Ensuring that study data is accurately collected and reported.</li><li>Reporting any study or participant problems.</li><li>Maintaining regulatory files at the study site.</li><li>Working with the Quality Assurance Monitor and data management staff to identify and resolve data and reporting issues.</li></ul><p>The Research Assistant’s role frequently also includes interacting with study participants by performing assessments (for example, assessing quality of life) and other protocol procedures.</p></div><div id="tabID-index-31" class="tab-pane fade"><h2>Nurses, Pharmacists, Counselors, Supervisors and Other Staff</h2><p>Nurses, pharmacists, and other staff are responsible for carrying out study procedures as described in the protocol (e.g., receiving and dispensing medications, conducting physical examinations, delivering behavioral interventions) and for assessing and reporting adverse events to appropriate staff.</p></div></div></div></div></div>

